Table 2.
Baseline CMR characteristics of patients and controls
| Amyloidosis | Controls | P-value | |
|---|---|---|---|
| LVEF (%) | 60.0 ± 13.2 | 66.1 ± 4.3 | 0.170 |
| IVS (mm) | 18.0 ± 4.6 | 8.0 ± 1.5 | < 0.001 |
| LVMi(g/m2) | 85.2 ± 25.1 | 45.0 ± 8.7 | < 0.001 |
| LVEDV (mL) | 130.1 ± 23.0 | 126.9 ± 34.0 | 0.8 |
| LVEDD (mm) | 46.2 ± 3.5 | 46.9 ± 4.6 | 0.678 |
| SV (mL) | 76.7 ± 16.3 | 84.5 ± 20.2 | 0.331 |
| RVEF (%) | 64.5 ± 9.5 | 62.8 ± 5.0 | 0.604 |
| RVEDV (mL) | 112.0 ± 30.5 | 130.1 ± 29.3 | 0.171 |
| GLS (%) | −19.7 ± 5.6 | −31.1 ± 5.5 | < 0.001 |
| GCS (%) | −29.8 ± 6.1 | −36.2 ± 3.3 | 0.007 |
| Long SRe | 1.7 ± 0.5 | 1.4 ± 0.4 | 0.076 |
| Circ SRe | 1.3 ± 0.3 | 1.7 ± 0.4 | 0.019 |
Circ circumferential, GLS global longitudinal strain, GCS global circumferential strain, IVS interventricular septum, Long longitudinal, LVEDD left ventricular end-diastolic diameter, LVEDV/RVEDV left/right ventricular end-diastolic volume, LVEF/RVEF left/right ventricular ejection fraction, LVMi left ventricular mass indexed to body surface area, SRe strain rate, SV stroke volume